{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:50:55Z","timestamp":1760028655033,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40256-019-00358-0","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T05:02:37Z","timestamp":1562562157000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guidelines on the Management of Blood Cholesterol"],"prefix":"10.1007","volume":"20","author":[{"name":"for the American Society for Preventive Cardiology","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-7324","authenticated-orcid":false,"given":"Nathan D.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezra A.","family":"Amsterdam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Khera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"358_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000625","author":"SM Grundy","year":"2018","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2018. \nhttps:\/\/doi.org\/10.1161\/cir.0000000000000625\n\n.","journal-title":"Circulation"},{"issue":"25","key":"358_CR2","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"Neil J. Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al.; American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889\u2013934. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2013.11.002\n\n. Erratum in: J Am Coll Cardiol. 2015;66(24):2812. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):3024\u20133025.","journal-title":"Journal of the American College of Cardiology"},{"key":"358_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.009","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2019.03.009\n\n.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"358_CR4","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","volume":"63","author":"Robert H. Eckel","year":"2014","unstructured":"Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al.; American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. 2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2960\u201384. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2013.11.003\n\n. Erratum in: J Am Coll Cardiol. 2014;63(25 Pt B):3027\u20138.","journal-title":"Journal of the American College of Cardiology"},{"issue":"15","key":"358_CR5","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jacc.2015.07.066","volume":"66","author":"Khurram Nasir","year":"2015","unstructured":"Nasir K, Bittencourt MS, Blaha MJ, Blankstein R, Agatson AS, Rivera JJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology\/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66(15):1657\u201368. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2015.07.066\n\n. Erratum in: J Am Coll Cardiol. 66(23):2686. Miemdema, Michael D [corrected to Miedema, Michael D].","journal-title":"Journal of the American College of Cardiology"},{"issue":"15","key":"358_CR6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/circulationaha.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbal\u00e1n R, \u0160pinar J, IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571\u201382. \nhttps:\/\/doi.org\/10.1161\/circulationaha.117.030950\n\n.","journal-title":"Circulation"},{"issue":"4","key":"358_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11606-015-3556-3","volume":"31","author":"JS Rana","year":"2016","unstructured":"Rana JS, Liu JY, Moffet HH, Jaffe M, Karter AJ. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med. 2016;31(4):387\u201393. \nhttps:\/\/doi.org\/10.1007\/s11606-015-3556-3\n\n.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"358_CR8","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2337\/dc11-0816","volume":"34","author":"S Malik","year":"2011","unstructured":"Malik S, Budoff MJ, Katz R, Blumenthal RS, Bertoni AG, Nasir K, et al. Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes: the multi-ethnic study of atherosclerosis. Diabetes Care. 2011;34(10):2285\u201390. \nhttps:\/\/doi.org\/10.2337\/dc11-0816\n\n.","journal-title":"Diabetes Care"},{"issue":"12","key":"358_CR9","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamacardio.2017.4191","volume":"2","author":"S Malik","year":"2017","unstructured":"Malik S, Zhao Y, Budoff M, Nasir K, Blumenthal RS, Bertoni AG, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol. 2017;2(12):1332\u201340. \nhttps:\/\/doi.org\/10.1001\/jamacardio.2017.4191\n\n.","journal-title":"JAMA Cardiol"},{"key":"358_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2019.01.014","author":"M Budoff","year":"2019","unstructured":"Budoff M, Backlund JC, Bluemke DA, Polak J, Bebu I, Schade D, DCCT\/EDIC Research Group, et al. The association of coronary artery calcification with subsequent incidence of cardiovascular disease in type 1 diabetes: the DCCT\/EDIC trials. JACC Cardiovasc Imaging. 2019. \nhttps:\/\/doi.org\/10.1016\/j.jcmg.2019.01.014\n\n.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"358_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, REDUCE-IT Investigators, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. \nhttps:\/\/doi.org\/10.1056\/nejmoa1812792\n\n.","journal-title":"N Engl J Med"},{"unstructured":"American Diabetes Association. Living standards of medical care in diabetes. \nhttp:\/\/care.diabetesjournals.org\/living-standards\n\n. Accessed 21 Apr 2019.","key":"358_CR12"},{"key":"358_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2019\/00014","author":"ND Wong","year":"2019","unstructured":"Wong ND, Shapiro MD. Interpreting the findings from the recent PCSK9 monoclonal antibody cardiovascular outcomes trials. Front Cardiovasc Med. 2019. \nhttps:\/\/doi.org\/10.3389\/fcvm.2019\/00014\n\n.","journal-title":"Front Cardiovasc Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00358-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-019-00358-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00358-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T23:22:47Z","timestamp":1594077767000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-019-00358-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1007\/s40256-019-00358-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2019,7,8]]},"assertion":[{"value":"8 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nathan D. Wong, PhD, has received research support through the University of California, Irvine, from Amgen, Amarin, Novo Nordisk, and Boehringer Ingelheim; speaking fees from Amarin and Sanofi; and consulting fees from Amarin and Novartis. Peter Toth, MD, PhD, notes speaking fees from Amarin, Amgen, Kowa, Nova Nordisk, Regeneron, and Sanofi, and consultant\/advisory board participation for Amarin, Amgen, Kowa, Nova Nordisk, Regeneron, and Sanofi. Christie Ballantyne, MD, has received speaking fees from Akcea, Amgen, Esperion, Novartis, Regeneron, and Sanofi-Synthelabo (all paid to institution, not individual), and consulting fees or honorarium from Akcea, Amarin, Amgen, Arrowhead, AstraZeneca, Boehringer Ingelheim, Esperion, Intercept, Janssen, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Regeneron, and Sanofi-Synthelabo. Ezra A. Amsterdam, MD, Amit Khera, MD, and Khurram Nasir, MD, MPH, declare no potential conflicts of interest that might be relevant to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}